Skip to main content

Medications for CDKL5 Deficiency Disorder

Other names: CDD; Cyclin-Dependent Kinase-Like 5 Deficiency Disorder

CDKL5 Deficiency Disorder (CDD) is a serious and rare form of genetic epilepsy.

CDD is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. The CDKL5 gene produces a protein that is important for normal brain development and function.

CDD is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. Most children affected by CDD cannot walk, talk, or feed themselves. 

Ztalmy (ganaxolone) is the first treatment approved specifically for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). Ztalmy works by exhibiting anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors.

Note: There are currently no drugs listed for "CDKL5 Deficiency Disorder".

See Seizures

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.